Skip to main content

Table 3 Univariate analysis of survival at day 28 for baseline covariates significantly different between the angiotensin II dose groups

From: Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial

 

Patients, n,  % (95% CI)

Hazard ratio* (95% CI)

P value

Angiotensin II > 5 ng kg−1 min−1

Angiotensin II ≤ 5 ng kg−1 min−1

Baseline MAP

 ≥ 65 mmHg

47, 44.7 (30.2–58.1)

64, 67.2 (54.2–77.2)

0.52 (0.29–0.92)

0.023

 < 65 mmHg

37, 37.4 (22.1–52.7)

15, 66.7 (37.5–84.6)

0.38 (0.14–1.00)

0.041

Baseline norepinephrine-equivalent dose

 < 0.5 µg kg−1 min−1

50, 47.4 (33.0–60.5)

67, 68.7 (56.1–78.3)

0.53 (0.30–0.95)

0.030

 ≥ 0.5 µg kg−1 min−1

34, 32.4 (17.6–48.0)

12, 58.3 (27.0–80.1)

0.45 (0.17–1.19)

0.100

Baseline angiotensin I

 < 72.3 pg/mL

12, 41.7 (15.2–66.5)

24, 66.7 (44.3–81.7)

0.49 (0.18–1.35)

0.160

 72.3 to < 253 pg/mL

14, 42.9 (17.7–66.0)

19, 57.9 (33.2–76.3)

0.56 (0.21–1.48)

0.234

 253 to < 676 pg/mL

25, 39.3 (20.5–57.6)

14, 85.7 (53.9–96.2)

0.18 (0.04–0.80)

0.011

 ≥ 676 pg/mL

23, 52.2 (30.5–70.0)

14, 50.0 (22.9–72.2)

1.02 (0.40–2.64)

0.962

Baseline angiotensin II

 < 23.85 pg/mL

14, 28.6 (8.8–52.4)

21, 71.4 (47.2–86.0)

0.29 (0.10–0.80)

0.011

 23.85 to < 83.75 pg/mL

11, 36.4 (11.2–62.7)

21, 71.4 (47.2–86.0)

0.37 (0.12–1.09)

0.060

 83.75 to < 299.5 pg/mL

25, 43.2 (23.5–61.5)

21, 57.1 (33.8–74.9)

0.64 (0.27–1.47)

0.285

 ≥ 299.5 pg/mL

24, 58.3 (36.4–75.0)

7, 57.1 (17.2–83.7)

1.01 (0.28–3.66)

0.993

  1. CI, confidence interval; MAP, mean arterial pressure
  2. *Hazard ratio/log-rank test result of treatment effect within subgroup